glp 1 agonist dpp 4 inhibitor Receptor Agonists and Inhibitors Mechanism of Action Cardiovascular effects of the DPP-4

However, up to 89% of participants taking efinopegdutide experienced gastrointestinal adverse events (mostly nausea, vomiting and diarrhoea) relative to 28% taking placebo and 60% taking liraglutide (86)

Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, et al

Using multifocal plane microscopy to reveal novel trafficking processes in the recycling pathway

A Strategic Decision Not a Simple Yes or No Employers must balance clinical effectiveness, cost sustainability, and operational feasibility

The Bridge program rules say that people can use the drugs to maintain weight loss. Thats because doctors have found that if people successfully lose weight using GLP-1 medications, then stop taking the drugs, they typically gain the weight back